ACHIEVEMENT OF CLINICAL REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS DEPENDING ON THE ACCP- AND RF-SEROLOGICAL STATUS

Georgian Med News. 2021 Sep:(318):99-104.

Abstract

In this clinical study, the effect of serological status of rheumatoid arthritis (RA) on the possibility and timing of clinical remission while taking the main non-biological disease modifying anti-rheumatic drugs (DMARD) was analyzed. The relationship between presence and levels of antibodies to cyclic citrullinated peptide (ACCP) and/or rheumatoid factor (RF) and remission in RA has also been studied. It was found that the frequency of remission, including early one (during the first 6 months of treatment), is three times higher in ACCP negative patients with RA. The rate of remission (ratio of early to total remission) does not depend on the serological status: about two thirds of patients in all analyzed groups achieve remission in the first 6 months of DMARD therapy. ACCP and RF titers in the onset of the disease do not influence the possibility of remission achievement.

MeSH terms

  • Arthritis, Rheumatoid* / drug therapy
  • Autoantibodies
  • Humans
  • Peptides, Cyclic
  • Rheumatoid Factor*

Substances

  • Autoantibodies
  • Peptides, Cyclic
  • cyclic citrullinated peptide
  • Rheumatoid Factor